- Home
- MMA vs BLRX Comparison
MMA vs BLRX Comparison
Compare MMA & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMA | BLRX |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | Australia | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 12.6M |
| IPO Year | 2023 | 2010 |
Fundamental Metrics
Financial Performance| Metric | MMA | BLRX |
|---|---|---|
| Price | $0.51 | $3.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 761.8K | 16.4K |
| Earning Date | 05-20-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $2.15 |
| 52 Week High | $2.00 | $4.86 |
Technical Indicators
Market Signals| Indicator | MMA | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.46 | 45.14 |
| Support Level | $0.35 | $2.62 |
| Resistance Level | $0.58 | $3.11 |
| Average True Range (ATR) | 0.04 | 0.23 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 53.28 | 38.10 |
Price Performance
Historical ComparisonAbout MMA Alta Global Group Limited
MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.